Point of Care Diagnostic Analyzer
press release
Biosynex subsidiary ProciseDx has entered into a strategic distribution agreement with Revvity EUROIMMUN US to distribute the ProciseDx platform in the United States and Canada. The platform is FDA de novo authorized for therapeutic drug monitoring of infliximab and adalimumab in patients with inflammatory bowel disease.
press release
BIOSYNEX reports a 10% revenue increase in Q3 2023, reaching 24.4 million euros, driven by strategic acquisitions and growth in non-COVID-19 diagnostic activities. The company confirms its 2023 annual revenue target of approximately 100 million euros, supported by the integration of Theradiag and Chembio, and new FDA authorizations for ProciseDx.
press release
Biosynex subsidiary ProciseDx announces the acquisition of two US patents for therapeutic drug monitoring (TDM) and reports FDA de novo authorization for infliximab and adalimumab TDM tests. The document also highlights the planned merger between Biosynex and Theradiag to strengthen their global position in biotherapy monitoring.
press release
Biosynex announces that its subsidiary ProciseDx has received FDA de novo authorization for therapeutic drug monitoring (TDM) tests for infliximab and adalimumab, enabling rapid quantitative results in 5 minutes for patients with inflammatory bowel disease (IBD).
press release
BIOSYNEX announces the acquisition of QUALIGEN Inc. by its subsidiary CHEMBIO Inc. to strengthen its industrial and commercial presence in the United States. The acquisition includes the Fastpack immunoassay platform, which is CE marked and FDA approved.
press release
BIOSYNEX announces the acquisition of the remaining capital of ProciseDx, strengthening its presence in the US market and its position in the biotherapy monitoring sector. The acquisition aims to leverage synergies between ProciseDx and Theradiag to develop point-of-care diagnostic solutions.
press release
BIOSYNEX announces the acquisition of a 75% stake in the Danish company MEDKONCEPT AS to expand its presence in the Nordic market, leveraging synergies for the distribution of rapid diagnostic tests and Point of Care solutions.
press release
BIOSYNEX announces that its partner ProciseDx has received FDA 510(k) clearance for the ProciseDx instrument and the ProciseDx CRP test. This milestone validates the TR-FRET technology platform for point-of-care quantitative testing, with plans for future expansion into biotherapy monitoring tests in the US market.
Biosynex
Conecte directamente con Biosynex para solicitar precios, muestras y plazos de entrega de Procise DX.
The Procise DX is a point-of-care diagnostic analyzer designed to provide laboratory-quality results directly at the patient's side. It is engineered for simplicity and speed, making it suitable for use by nursing staff in primary care settings.
